Company Overview - Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [2] - The company is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan [2] - Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX) [2] Upcoming Events - Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in fireside chats at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025 [1][2] - Each session will be webcast live and available on demand following the events [2] Investor Relations - For more information regarding Telix, including share price, SEC filings, and investor presentations, the Telix Investor Relations website can be visited [3] - Contact information for investor relations includes Ms. Kyahn Williamson for global inquiries and Annie Kasparian for U.S. inquiries [4]
Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference